Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study

Detalles Bibliográficos
Autores principales: Hughes, Derralynn A., Nicholls, Kathleen, Sunder‐Plassmann, Gere, Jovanovic, Ana, Feldt‐Rasmussen, Ulla, Schiffmann, Raphael, Giugliani, Robert, Jain, Vipul, Viereck, Chris, Castelli, Jeffrey P., Skuban, Nina, Barth, Jay A., Bichet, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593787/
https://www.ncbi.nlm.nih.gov/pubmed/30920142
http://dx.doi.org/10.1002/ajmg.a.61105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593787/
https://www.ncbi.nlm.nih.gov/pubmed/30920142
http://dx.doi.org/10.1002/ajmg.a.61105

Ejemplares similares